An interventional study of Branched-Chain Amino Acids (BCAA) Supplementation in Myopia Progressing and Myopia, sponsored by Zhongda Hospital. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Zhongda Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 222 studies in Myopia with a site in China — 80 open to participants now, 102 under way, 4 of them phase 3. Myopia · China.
Among the 222 studies in Myopia with a site in China, this one is the 101st largest by planned enrollment of the 155 interventional ones that give a count, is one of 24 that started in 2026, is one of 136 with no phase, reaches primary completion later than 49 of the 101 other live ones, and was the 204th registered.
1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →80 of the 222 studies in Myopia with a site in China are open now. Recruiting first, the newest first:
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 3–6
Beijing Tongren Hospital · Sites in China
Healthy volunteers
Zhongshan Ophthalmic Center, Sun Yat-sen University · Sites in China
Ages 6–18 · Healthy volunteers
CooperVision International Limited (CVIL) · Sites in China
Ages 8–10
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 6–11 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 25 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
222 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 8 · Phase 4 7
First in 2005; this study’s year is marked. 24 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 104 is above the median of 79 across 929 interventional studies indexed under Myopia.
Median enrollment 150 across the 155 interventional studies, 1,000 across the 67 observational. Of the 77 that completed or were terminated, 5 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 222 have an industry lead sponsor. The 10 most frequent:
Zhongda Hospital is the lead sponsor of 104 studies on the registry; 42 are open to participants now.
Zhongda Hospital has 1 study filed under Myopia — fewer than ten, so there is no comparison to draw.
35 of the studies in Myopia with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06708156Phase 3Oupushifang Pharmaceutical Technology Co., Ltd.The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression | 2026-12-31 |
| NCT07585877Zhongda HospitalEffect of Branched-Chain Amino Acid Supplementation on Myopia Progression | 2026-12-30 |
| NCT07119723Tianjin Medical University Eye HospitalEnvironmental Factors and Myopia Prevalence Among Uyghur Students in Remote China | 2026-12-30 |
| NCT07008001SightGlass Vision, Inc.Assessment of DOT Spectacles in Chinese Children Extension | 2026-12-31 |
| NCT06667037Zhongshan Ophthalmic Center, Sun Yat-sen UniversityOrthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control | 2026-12-31 |
Add all 35 to your calendar (.ics) → With an account.
Among the 222 studies in Myopia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a randomized controlled trial designed to evaluate whether branched-chain amino acid (BCAA) supplementation can help slow the progression of myopia in young adults.
Eligible participants will be randomly assigned to receive either BCAA supplementation combined with standard spectacle correction or standard spectacle correction with a matching placebo. The intervention period will last approximately six months.
Participants will undergo regular follow-up examinations, including measurements of visual acuity, refractive error, axial length, intraocular pressure, and other ocular parameters. Additional assessments such as ocular imaging (including OCTA), physical examinations, and blood tests will also be performed to evaluate eye health and metabolic indicators.
The main purpose of this study is to investigate whether BCAA supplementation can provide a safe and effective nutritional strategy to slow myopia progression and improve understanding of the relationship between amino acid metabolism and ocular growth.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive daily oral branched-chain amino acid (BCAA) supplementation in addition to standard spectacle correction. The intervention is administered for approximately 6 months to evaluate its effect on myopia progression and ocular parameters.
Dietary Supplement: Branched-Chain Amino Acids (BCAA) Supplementation
Participants in the control group will receive standard spectacle correction combined with a placebo identical in appearance to the BCAA supplement, without active BCAA ingredients. They will be followed for approximately 6 months to evaluate myopia progression and ocular outcomes.
Participants will receive oral branched-chain amino acids (BCAA), including leucine, isoleucine, and valine, as a dietary supplement in addition to standard spectacle correction. The intervention is administered daily for approximately 6 months. The supplement is a commercially available nutritional product obtained via cross-border e-commerce channels and is not intended as a therapeutic drug. The aim is to evaluate the effect of BCAA supplementation on myopia progression and ocular biometric parameters.
Also known as: BCAA, Branched-chain amino acids
Change in axial length
Axial length (AL) will be measured in both eyes using optical biometry at baseline, 3 months, and 6 months. The primary outcome is the change in axial length from baseline to 6 months, comparing the BCAA supplementation plus spectacle correction group with the spectacle correction only group.
Time frame: Baseline to 6 months
Change in spherical equivalent refractive error
Cycloplegic spherical equivalent (SE) will be measured using autorefractometry under cycloplegia at baseline, 3 months, and 6 months. The primary outcome is the change in spherical equivalent refractive error from baseline to 6 months, comparing the BCAA supplementation group with the control group.
Time frame: Baseline to 6 months
Superficial retinal vessel density
Superficial retinal vessel density will be measured in both eyes using OCTA in foveal, parafoveal, and perifoveal regions. Sectoral measurements (temporal, superior, nasal, and inferior) will be obtained, and the final value will be calculated as the mean of all regions, reported as a percentage (%).
Time frame: Baseline and 6 months
Deep retinal vessel density
Deep retinal vessel density will be measured in both eyes using OCTA across ETDRS regions. Sectoral measurements will be obtained, and the final value will be calculated as the mean of all regions, reported as a percentage (%).
Time frame: Baseline and 6 months
Choriocapillaris perfusion density
Choriocapillaris perfusion will be measured in both eyes using OCTA across foveal, parafoveal, and perifoveal regions. Sectoral measurements will be obtained, and the final value will be calculated as the mean of all regions, reported as a percentage (%).
Time frame: Baseline and 6 months
Retinal perfusion density
Retinal perfusion density will be measured in both eyes using OCTA across ETDRS regions, including full retinal perfusion and large-vessel-excluded perfusion. Sectoral measurements will be obtained, and the final value will be calculated as the mean of all regions, reported as a percentage (%).
Time frame: Baseline and 6 months
Family Ocular History
Definition: Baseline refractive status of parents based on self-reported highest degree of myopia in either eye. Variable type: Categorical Measurement: Self-reported parental myopia status categorized as none, low (≤300°), moderate (300-600°), and high (≥600°).
Time frame: Baseline
Nutritional Supplement Use
Definition: Baseline information on participants' use of any nutritional or dietary supplements. Variable type: Binary (Yes/No) Measurement: Self-reported use of dietary or nutritional supplements (Yes/No).
Time frame: Baseline
Protein Allergy History
Definition: Baseline assessment of whether participants have a documented or self-reported history of protein allergy. Variable type: Binary (Yes/No) Measurement: Self-reported history of protein allergy (Yes/No).
Time frame: Baseline
Parental Education Level
Parental education level at baseline, self-reported via structured questionnaire. Education levels are categorized as: primary school or below, junior/high school, university, and master's degree or above.Variable Type:Categorical
Time frame: Baseline
Daily Screen Time
Average daily time spent using electronic devices (including television, mobile phone, computer, and projection screen) over the past week, assessed by questionnaire. Variable type: Categorical.
Time frame: Baseline
Eye Rest and Break Behavior
Definition: Frequency of eye breaks during near work activities. Variable type: Categorical Measurement: Self-reported duration of continuous near work before rest (≤30 min, 30-60 min, 1-2 h, 2-3 h, ≥3 h).
Time frame: Baseline
Sleep Duration
Definition: Average daily sleep duration over the past week. Variable type: Continuous Measurement: Self-reported average sleep time (hours and minutes per day).
Time frame: Baseline
Staple food intake frequency
Frequency and quantity of staple food intake, including rice, wheat-based products, corn products, mixed beans, tubers, and fried flour-based foods, assessed using a semi-quantitative food frequency questionnaire.
Time frame: Baseline
Protein-rich food intake frequency
Frequency and quantity of protein-rich food consumption, including soybeans and soy products, meat (pork, beef, lamb, poultry), aquatic products (fish, shrimp, shellfish), eggs, and dairy products, assessed using a semi-quantitative food frequency questionnaire.
Time frame: Baseline
Vegetable intake frequency
Frequency and quantity of vegetable intake, including dark green vegetables, red/orange vegetables, purple vegetables, and light-colored vegetables, assessed using a semi-quantitative food frequency questionnaire.
Time frame: Baseline
Fruit intake frequency
Frequency and quantity of fruit intake, including pome fruits, citrus fruits, stone fruits, berries, melons, and tropical fruits, assessed using a semi-quantitative food frequency questionnaire.
Time frame: Baseline
Dairy product intake frequency
Frequency and quantity of dairy product consumption, including liquid milk, milk powder, and yogurt, assessed using a semi-quantitative food frequency questionnaire.
Time frame: Baseline
Snack and sugary food intake frequency
Frequency and quantity of intake of snacks and sugary foods, including baked goods, nuts, processed snacks, sweets, and sugar-sweetened beverages, assessed using a semi-quantitative food frequency questionnaire.
Time frame: Baseline
Temporal Superior RNFL Thickness
Peripapillary retinal nerve fiber layer (RNFL) thickness in the temporal superior (TU) sector measured by optical coherence tomography angiography (OCTA), reported in micrometers (µm).
Time frame: Baseline and 6 months
Superior Temporal RNFL Thickness
Peripapillary RNFL thickness in the superior temporal (ST) sector measured by OCTA, reported in micrometers (µm).
Time frame: Baseline and 6 months
Superior Nasal RNFL Thickness
Peripapillary RNFL thickness in the superior nasal (SN) sector measured by OCTA, reported in micrometers (µm).
Time frame: Baseline and 6 months
Nasal Superior RNFL Thickness
Peripapillary RNFL thickness in the nasal superior (NU) sector measured by OCTA, reported in micrometers (µm).
Time frame: Baseline and 6 months
Nasal Inferior RNFL Thickness
Peripapillary RNFL thickness in the nasal inferior (NL) sector measured by OCTA, reported in micrometers (µm).
Time frame: Baseline and 6 months
Inferior Nasal RNFL Thickness
Peripapillary RNFL thickness in the inferior nasal (IN) sector measured by OCTA, reported in micrometers (µm).
Time frame: Baseline and 6 months
Inferior Temporal RNFL Thickness
Peripapillary RNFL thickness in the inferior temporal (IT) sector measured by OCTA, reported in micrometers (µm).
Time frame: Baseline and 6 months
Temporal Inferior RNFL Thickness
Peripapillary RNFL thickness in the temporal inferior (TL) sector measured by OCTA, reported in micrometers (µm).
Time frame: Baseline and 6 months
Global Average Peripapillary RNFL Thickness
Global average peripapillary retinal nerve fiber layer (RNFL) thickness measured by optical coherence tomography angiography (OCTA), calculated as the mean thickness across all peripapillary regions, and reported in micrometers (µm).
Time frame: Baseline and 6 months
Optic Disc Area
Optic disc area measured in both eyes using optical coherence tomography angiography (OCTA), reported in square millimeters (mm²).
Time frame: Baseline and 6 months
Neuroretinal Rim Area
Neuroretinal rim area measured in both eyes using OCTA, reported in square millimeters (mm²).
Time frame: Baseline and 6 months
Optic Cup Volume
Optic cup volume measured in both eyes using OCTA, reported in cubic millimeters (mm³).
Time frame: Baseline and 6 months
Cup-to-Disc Ratio
Cup-to-disc ratio measured in both eyes using OCTA, defined as the ratio of optic cup diameter to optic disc diameter (unitless).
Time frame: Baseline and 6 months
Vertical Cup-to-Disc Ratio
Vertical cup-to-disc ratio measured in both eyes using OCTA (unitless).
Time frame: Baseline and 6 months
Horizontal Cup-to-Disc Ratio
Horizontal cup-to-disc ratio measured in both eyes using OCTA (unitless).
Time frame: Baseline and 6 months
Peripapillary Temporal Superior Sector Vessel Density
Peripapillary microvascular vessel density in the temporal superior (TU) sector measured in both eyes using optical coherence tomography angiography (OCTA), reported as vessel density percentage (%).
Time frame: Baseline and 6 months
Peripapillary Superior Temporal Sector Vessel Density
OCTA-derived vessel density in the superior temporal (ST) peripapillary sector in both eyes,reported as vessel density percentage (%).
Time frame: Baseline and 6 months
Peripapillary Superior Nasal Sector Vessel Density
OCTA-derived vessel density in the superior nasal (SN) peripapillary sector in both eyes,reported as vessel density percentage (%).
Time frame: Baseline and 6 months
Peripapillary Nasal Superior Sector Vessel Density
OCTA-derived vessel density in the nasal superior (NU) peripapillary sector in both eyes,reported as vessel density percentage (%).
Time frame: Baseline and 6 months
Peripapillary Nasal Inferior Sector Vessel Density
OCTA-derived vessel density in the nasal inferior (NL) peripapillary sector in both eyes,
Time frame: Baseline and 6 months
Peripapillary Inferior Nasal Sector Vessel Density
OCTA-derived vessel density in the inferior nasal (IN) peripapillary sector in both eyes,reported as vessel density percentage (%).
Time frame: Baseline and 6 months
Peripapillary Inferior Temporal Sector Vessel Density
OCTA-derived vessel density in the inferior temporal (IT) peripapillary sector in both eyes,reported as vessel density percentage (%).
Time frame: Baseline and 6 months
Peripapillary Temporal Inferior Sector Vessel Density
OCTA-derived vessel density in the temporal inferior (TL) peripapillary sector in both eyes,reported as vessel density percentage (%).
Time frame: Baseline and 6 months
Global Peripapillary Vessel Density
Mean peripapillary microvascular vessel density calculated across all peripapillary sectors in both eyes using OCTA,reported as vessel density percentage (%).
Time frame: Baseline and 6 months
Full Macular Retinal Thickness
Full retinal thickness in the macular region measured in both eyes using optical coherence tomography angiography (OCTA), including foveal, parafoveal, and perifoveal regions across temporal, superior, nasal, and inferior sectors.
Time frame: Baseline and 6 months
Macular Inner Retinal Layer Thickness
Inner retinal layer thickness in the macular region measured in both eyes using OCTA, assessed at foveal, parafoveal, and perifoveal regions across four quadrants (temporal, superior, nasal, inferior).
Time frame: Baseline and 6 months
Macular Outer Retinal Layer Thickness
Outer retinal layer thickness in the macular region measured in both eyes using OCTA, including foveal, parafoveal, and perifoveal regions across temporal, superior, nasal, and inferior sectors.
Time frame: Baseline and 6 months
Foveal Avascular Zone Area
Foveal avascular zone (FAZ) area measured in both eyes using optical coherence tomography angiography (OCTA).
Time frame: Baseline and 6 months
FAZ-300 Superficial Capillary Plexus Perfusion Density
Perfusion density in a 300 μm annular region surrounding the FAZ in the superficial capillary plexus measured using OCTA.
Time frame: Baseline and 6 months
FAZ-300 Deep Capillary Plexus Perfusion Density
Perfusion density in a 300 μm annular region surrounding the FAZ in the deep capillary plexus measured using OCTA.
Time frame: Baseline and 6 months
FAZ-300 Full Retinal Perfusion Density
Perfusion density in a 300 μm annular region surrounding the FAZ across full retinal layers measured using OCTA.
Time frame: Baseline and 6 months
Alanine Aminotransferase (ALT)
Serum alanine aminotransferase (ALT) measured in fasting venous blood using standard laboratory methods. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.
Time frame: Baseline and 6 months
Aspartate Aminotransferase (AST)
Serum AST measured using standard laboratory methods in fasting venous blood. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.
Time frame: Baseline and 6 months
Total Bilirubin (TBil)
Serum total bilirubin measured in fasting venous blood. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.
Time frame: Baseline and 6 months
Serum Creatinine (Scr)
Serum creatinine measured in fasting venous blood using standard laboratory methods. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.
Time frame: Baseline and 6 months
Blood Urea Nitrogen (BUN)
BUN measured in fasting venous blood using standard laboratory methods. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.
Time frame: Baseline and 6 months
Uric Acid (UA)
Serum uric acid measured in fasting venous blood using standard laboratory methods. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.
Time frame: Baseline and 6 months
Fasting Plasma Glucose (FPG)
Fasting plasma glucose measured in fasting venous blood using standard laboratory methods. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.
Time frame: Baseline and 6 months
Total Cholesterol (TC)
Serum total cholesterol measured in fasting venous blood using standard laboratory methods. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.
Time frame: Baseline and 6 months
Triglycerides (TG)
Serum triglycerides measured in fasting venous blood using standard laboratory methods. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.
Time frame: Baseline and 6 months
High-Density Lipoprotein Cholesterol (HDL-C)
HDL cholesterol measured in fasting venous blood using standard laboratory methods. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.
Time frame: Baseline and 6 months
Low-Density Lipoprotein Cholesterol (LDL-C)
LDL cholesterol measured in fasting venous blood using standard laboratory methods. Values will be analyzed as continuous variables and categorized as normal or abnormal based on clinical reference ranges.
Time frame: Baseline and 6 months
Sex of Participants
Participant sex recorded at baseline using structured questionnaire.
Time frame: Baseline
Age of Participants
Age calculated from date of birth at baseline using structured questionnaire.
Time frame: Baseline
Ethnicity of Participants
Ethnicity recorded at baseline using structured questionnaire.
Time frame: Baseline
Body Mass Index (BMI)
BMI calculated from weight and height measured at baseline.Units:kg/m², Type:Continuous
Time frame: Baseline
Household Residence
Household residence (urban/rural) recorded at baseline using structured questionnaire.Type:Categorical
Time frame: Baseline
Annual Household Income
Annual household income recorded at baseline using structured questionnaire.Type : categorical
Time frame: Baseline
Study Pressure Level
Self-reported level of study pressure and workload, assessed by questionnaire with four levels ranging from low to high. Variable type: Categorical.
Time frame: Baseline
Unhealthy Visual Habits
Presence of unhealthy visual habits (e.g., reading under strong sunlight, using screens in dark environments, improper posture during near work), assessed by multiple-choice questionnaire. Variable type: Categorical (multiple response).
Time frame: Baseline
Lighting Conditions During Nighttime Near Work
Lighting conditions used during near-work activities after dark (e.g., desk lamp, ceiling light), assessed by questionnaire. Variable type: Categorical.
Time frame: Baseline
Moderate-to-Vigorous Physical Activity Duration
Average daily duration of moderate-to-vigorous physical activity (e.g., brisk walking, running, jumping rope, cycling) over the past week, assessed by questionnaire. Variable type: Categorical.
Time frame: Baseline
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.
Of 202 non-industry interventional studies with no phase under Myopia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 11 months is below that.
Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amino Acids, Branched-Chain